Making the most of tradition and constantly seeking innovation: that’s what guides Dompé in its mission to satisfy the therapeutic needs of Patients by focusing its offer on the Primary Care and rare and orphan disease areas. The company carries out all activities involved in the value chain of the pharmaceutical industry and is divided into four departments: Research & Development, Manufacturing, Primary Care and rare Q.
The R&D department identifies and develops new molecules for the rare disease area and creates new proprietary product formulations with a view to further strengthening the Company's presence in the Primary Care area on both national and international levels. The department is also distinguished by its productiovn of recombinant proteins in accordance with the very highest standards of quality and its distinctive, high-skill analytical offer.
The Manufacturing department supervises the production of Dompé proprietary products, maintaining a high level of efficiency and is oriented towards the production of new, high-tech and quality products at competitive prices.
The Primary Care department works in close collaboration with Doctors and Pharmacists to provide Patients with effective solutions for treating the symptoms of the main diseases of the respiratory and osteoarticular systems.
La Rare Q department operates in a sustainable, socially important niche, to meet the therapeutic needs of patients with rare diseases, offering drugs that are the fruit of proprietary research and therapeutic solutions purchased from partners.
Dompé spa VAT no. 01241900669 Registered office: Via Campo di Pile snc, L'Aquila (AQ) Registry office of L'Aquila Entry no. on company register (REA) AQ -74816 Capital stock: € 44,709,874.00 fully paid Sole partner Control and coordination body: Dompé farmaceutici spa
